SuperworthElicio Therapeutics ELTX
- Market cap
- $49.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Elicio Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $7.3M+58% | $6.2M+3748% | $7.6M+38% | $8.2M+66% | $7.2M−1% | $10.7M+74% | $7.8M+3% | $7M−14% | $5M−30% | $5.1M−53% | $6.8M−13% | $6.8M−3% |
| SG&A | $3.5M+198% | $3.2M−14% | $2.7M+16% | $2.7M−3% | $3.1M−11% | $2.8M−15% | $3M+10% | $3.1M+12% | $3M−4% | $3.8M+36% | $3.8M+30% | $3.6M+17% |
| −$10.8M+87% | −$9.4M+33% | −$10.2M+31% | −$10.9M+41% | −$10.3M−4% | −$13.5M+44% | −$10.7M+5% | −$10.1M−8% | −$8M−22% | −$8.8M−34% | −$10.6M−1% | −$10.4M+3% | |
| Interest expense | $1K−100% | $2K−98% | $36K−90% | $49K−93% | $137K+13600% | $234K+11600% | $176K+389% | $194K+296% | $426K+211% | $337K+44% | $407K+131% | $410K+111% |
| Net income | −$10.7M+48% | −$8.9M+39% | −$11.8M+47% | −$7.2M−4% | −$18.8M+77% | −$14M+57% | −$11.2M−5% | −$10.6M+46% | −$10.1M−47% | −$7.7M−45% | −$11.8M+6% | −$8.2M−22% |
| −$1.27−94% | −$1.05−50% | −$1.15−95% | −$0.64−76% | −$1.39+9% | −$1.03−2% | −$0.87−24% | −$0.66+3% | −$0.60−57% | −$0.50−52% | −$0.65−25% | −$0.43−35% | |
| 8.4M+2538% | 8.5M+2557% | 10.3M+3070% | 11.3M+290% | 13.6M+62% | 13.6M+60% | 13M+26% | 16.1M+42% | 16.7M+23% | 15.5M+14% | 18.2M+41% | 19.2M+20% |
Gross profit: 8 periods, Q1 FY20 to Q4 FY21: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21 and Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Elicio Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ELTXElicio Therapeutics | $49.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| Peer median | $73.4M | 12.0× | 19.6× | 0.9× | −9% | 3.3% |
More on Elicio Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .